215 related articles for article (PubMed ID: 31769737)
61. CSPG4-specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNA.
Riccardo F; Iussich S; Maniscalco L; Lorda Mayayo S; La Rosa G; Arigoni M; De Maria R; Gattino F; Lanzardo S; Lardone E; Martano M; Morello E; Prestigio S; Fiore A; Quaglino E; Zabarino S; Ferrone S; Buracco P; Cavallo F
Clin Cancer Res; 2014 Jul; 20(14):3753-62. PubMed ID: 24874834
[TBL] [Abstract][Full Text] [Related]
62. Chimeric Antigen Receptors Based on Low Affinity Mutants of FcεRI Re-direct T Cell Specificity to Cells Expressing Membrane IgE.
Ward DE; Fay BL; Adejuwon A; Han H; Ma Z
Front Immunol; 2018; 9():2231. PubMed ID: 30364107
[TBL] [Abstract][Full Text] [Related]
63. Novel IgE peptide-based vaccine prevents the increase of IgE and down-regulates elevated IgE in rodents.
Peng Z; Liu Q; Wang Q; Rector E; Ma Y; Warrington R
Clin Exp Allergy; 2007 Jul; 37(7):1040-8. PubMed ID: 17581197
[TBL] [Abstract][Full Text] [Related]
64. Melanoma-associated chondroitin sulphate proteoglycan as a new target antigen for CD4+ T cells in melanoma patients.
Erfurt C; Müller E; Emmerling S; Klotz C; Hertl M; Schuler G; Schultz ES
Int J Cancer; 2009 May; 124(10):2341-6. PubMed ID: 19173283
[TBL] [Abstract][Full Text] [Related]
65. Immunoglobulin G3 monoclonal antibody directed to Tn antigen (tumor-associated alpha-N-acetylgalactosaminyl epitope) that does not cross-react with blood group A antigen.
Takahashi HK; Metoki R; Hakomori S
Cancer Res; 1988 Aug; 48(15):4361-7. PubMed ID: 3390832
[TBL] [Abstract][Full Text] [Related]
66. IgE immunotherapy: a novel concept with promise for the treatment of cancer.
Josephs DH; Spicer JF; Karagiannis P; Gould HJ; Karagiannis SN
MAbs; 2014; 6(1):54-72. PubMed ID: 24423620
[TBL] [Abstract][Full Text] [Related]
67. Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement.
Imai M; Ohta R; Varela JC; Song H; Tomlinson S
Cancer Res; 2007 Oct; 67(19):9535-41. PubMed ID: 17909064
[TBL] [Abstract][Full Text] [Related]
68. Monoclonal antibody AA4, which inhibits binding of IgE to high affinity receptors on rat basophilic leukemia cells, binds to novel alpha-galactosyl derivatives of ganglioside GD1b.
Guo NH; Her GR; Reinhold VN; Brennan MJ; Siraganian RP; Ginsburg V
J Biol Chem; 1989 Aug; 264(22):13267-72. PubMed ID: 2526814
[TBL] [Abstract][Full Text] [Related]
69. Functional roles of CSPG4/NG2 in chondrosarcoma.
Jamil NS; Azfer A; Worrell H; Salter DM
Int J Exp Pathol; 2016 Apr; 97(2):178-86. PubMed ID: 27292772
[TBL] [Abstract][Full Text] [Related]
70. Mouse mammary epithelial cells produce basement membrane and cell surface heparan sulfate proteoglycans containing distinct core proteins.
Jalkanen M; Rapraeger A; Bernfield M
J Cell Biol; 1988 Mar; 106(3):953-62. PubMed ID: 2964452
[TBL] [Abstract][Full Text] [Related]
71. A Novel, Fully Human Anti-fucosyl-GM1 Antibody Demonstrates Potent
Ponath P; Menezes D; Pan C; Chen B; Oyasu M; Strachan D; LeBlanc H; Sun H; Wang XT; Rangan VS; Deshpande S; Cristea S; Park KS; Sage J; Cardarelli PM
Clin Cancer Res; 2018 Oct; 24(20):5178-5189. PubMed ID: 30021910
[No Abstract] [Full Text] [Related]
72. Targeting CSPG4 for isolation of melanoma cell-derived exosomes from body fluids.
Ferrone S; Whiteside TL
HNO; 2020 Feb; 68(2):100-105. PubMed ID: 32006045
[TBL] [Abstract][Full Text] [Related]
73. Functional study of a monoclonal antibody to IgE Fc receptor (Fc epsilon R2) of eosinophils, platelets, and macrophages.
Capron M; Jouault T; Prin L; Joseph M; Ameisen JC; Butterworth AE; Papin JP; Kusnierz JP; Capron A
J Exp Med; 1986 Jul; 164(1):72-89. PubMed ID: 2425032
[TBL] [Abstract][Full Text] [Related]
74. Target-specific activation of mast cells by immunoglobulin E reactive with a renal cell carcinoma-associated antigen.
Luiten RM; Fleuren GJ; Warnaar SO; Litvinov SV
Lab Invest; 1996 Feb; 74(2):467-75. PubMed ID: 8780164
[TBL] [Abstract][Full Text] [Related]
75. Structural deciphering of the NG2/CSPG4 proteoglycan multifunctionality.
Tamburini E; Dallatomasina A; Quartararo J; Cortelazzi B; Mangieri D; Lazzaretti M; Perris R
FASEB J; 2019 Mar; 33(3):3112-3128. PubMed ID: 30550356
[TBL] [Abstract][Full Text] [Related]
76. Rat basophil leukaemia (RBL) cells sensitized with low affinity IgE respond to high valency antigen.
Collins AM; Basil M; Nguyen K; Thelian D
Clin Exp Allergy; 1996 Aug; 26(8):964-70. PubMed ID: 8877164
[TBL] [Abstract][Full Text] [Related]
77. Functional and clinical relevance of chondroitin sulfate proteoglycan 4.
Campoli M; Ferrone S; Wang X
Adv Cancer Res; 2010; 109():73-121. PubMed ID: 21070915
[TBL] [Abstract][Full Text] [Related]
78. Tumor-reactive CD4+ T cell responses to the melanoma-associated chondroitin sulphate proteoglycan in melanoma patients and healthy individuals in the absence of autoimmunity.
Erfurt C; Sun Z; Haendle I; Schuler-Thurner B; Heirman C; Thielemans K; van der Bruggen P; Schuler G; Schultz ES
J Immunol; 2007 Jun; 178(12):7703-9. PubMed ID: 17548607
[TBL] [Abstract][Full Text] [Related]
79. Engineering and stable production of recombinant IgE for cancer immunotherapy and AllergoOncology.
Crescioli S; Chiaruttini G; Mele S; Ilieva KM; Pellizzari G; Spencer DIR; Gardner RA; Lacy KE; Spicer JF; Tutt ANJ; Wagner GK; Karagiannis SN
J Allergy Clin Immunol; 2018 Apr; 141(4):1519-1523.e9. PubMed ID: 29360527
[No Abstract] [Full Text] [Related]
80. Characterization of new rat anti-mouse IgE monoclonals and their use along with chimeric IgE to further define the site that interacts with Fc epsilon RII and Fc epsilon RI.
Keegan AD; Fratazzi C; Shopes B; Baird B; Conrad DH
Mol Immunol; 1991 Oct; 28(10):1149-54. PubMed ID: 1717839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
